Added 5 months ago Drug news
Takeda announced that the National Institute for Health and Clinical Excellence (NICE) has issued its Final Appraisal Determination recommending Takhzyro...
Added 5 months ago Drug news
ADMA Biologics, Inc. announces the commercial relaunch and its first commercial sales of Bivigam for primary humoral immunodeficiency
ADMA Biologics, Inc. a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures and markets three approved plasma-derived biologics...
Added 7 months ago Drug news
Grifols announced that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the FDA. Xembify is used to treat...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.
The epgonline.org team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
This part of the European Fungal Infection Study Group (EFISG) of the European Society of Clinical Microbiology and Infectious Diseases...
Added 7 years ago
Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra®)...
Added 1 year ago
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection.
Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders.
Added 2 years ago
Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders
Human immunoglobulin is an established replacement therapy for patients with primary immunodeficiency disorders (PIDs). Recombinant human hyaluronidase (rHuPH20) is a...
Added 5 years ago
Lauren McCracken works for our sister agency Digital Medical Communications (DMC Ltd) as an Associate Medical Writer. Lauren is very passionate about healthcare and how technology can improve treatments, and has written a blog series 'Transforming lives through technology'... Read more
When should AIT be used to treat your patients with allergies? Is it right for every allergy? And do we really know the long-term effects of this treatment? This blog highlights some of the talking points surrounding AIT discussed at this year’s EAACI Congress.